Clozapine-induced myocarditis
Authors:
Jana Drahozalová 1; Lucie Kališová 1; Veronika Krejčí 2,3
Authors‘ workplace:
Klinika psychiatrie a neuropsychiatrie 2. LF UK a ÚVN – VFN Praha
1; Oddělení klinické farmacie, ÚVN – VFN Praha
2; Farmakologický ústav 1. LF UK a VFN v Praze
3
Published in:
Čes. a slov. Psychiat., 121, 2025, No. 5, pp. 209-215.
Category:
Review
doi:
https://doi.org/10.48095/cccsp202520
Overview
Clozapine is the mainstay of treatment for drug - -resistant schizophrenia and the only antipsychotic with a proven effect in reducing suicidal behavior. Despite its efficacy, its use is limited by severe adverse effects, especially hematological and cardiac ones. Serious cardiac complications of treatment include clozapine-induced myocarditis (CIM), which occurs within the first few weeks of titration and can be fatal. The pathophysiology of CIM is not yet fully understood; hypersensitivity immune reactions, direct toxic effects of metabolites, oxidative stress, and other mechanisms are assumed. The article summarizes current knowledge on the diagnosis, treatment, and prevention of clozapine-induced myocarditis.
Keywords:
myocarditis – clozapine – side-effects
Sources
1. Hippius H. A historical perspective of clozapine. J Clin Psychiatry 1999; 60 (Suppl 12): 22–23.
2. Idänpään-Heikkilä J, Alhava E, Olkinuora M, Palva IP. Clozapine and agranulocytosis. Lancet 1975; 2 (7935): 611. doi: 10.1016/S0140-673 6 (75) 90329-0.
3. Kane J, Honigfeld G, Singer J et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45 (9): 789–796. doi: 10.1001/archpsyc.1988.01800330013001.
4. Meltzer HY, Alphs L, Green AI et al. Clozapine treatment for suicidality in schizophrenia: InterSePT. Arch Gen Psychiatry 2003; 60 (1): 82–91. doi: 10.1001/archpsyc.60.1.82.
5. Kašpárek T, Ustohal L. Léčba akutní epizody schizofrenie. Doporučené postupy psychiatrické péče Psychiatrické společnosti ČLS JEP. [online]. Dostupné z: https: //postupy-pece.psychiatrie.cz.
6. Švestka J. Clozapin: prototyp antipsychotik nové generace. Praha: Maxdorf 1998.
7. Mayerová M, Horská K, Ustohal L. Klozapin, moderní antipsychotikum s dlouhou tradicí. Praha: Galén 2021.
8. Mohr P, Brunovský M, Páleníček T. Klinická psychofarmakologie 2. Praha: Maxdorf 2025.
9. De Leon J, Ruan CJ, Schoretsanitis G et al. A rational use of clozapine adverse drug reactions. Schizophr Bull 2020; 46 (1): 1–3. doi: 10.1093/schbul/sbz146.
10. Kopeček M, Švancer P, Masopust J. Novinky v léčbě schizofrenie. Psychiatrie 2022; 26 (2): 93–97.
11. Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354 (9193): 1841–1845. doi: 10.1016/S0140-6736 (99) 10427-3.
12. Bellissima BL, Tingle MD, Cicović A et al. A systematic review of clozapine-induced myocarditis. Int J Cardiol 2018; 259 : 122–129. doi: 10.1016/j.ijcard.2018.01.120.
13. Vickers M et al. Risk factors for clozapine-induced myocarditis: systematic review. Acta Psychiatr Scand 2022; 145 (5): 442–455. doi: 10.1111/acps.13424.
14. Ronaldson KJ, Fitzgerald PB, Taylor AJ et al. Rapid clozapine titration and myocarditis risk. Aust N Z J Psychiatry 2012; 46 (6): 458–465. doi: 10.1177/0004867412438876.
15. De Las Cuevas C, Arrojo-Romero M, Ruan CJ et al. Clozapine-induced myocarditis in children and adolescents: a pharmacovigilance study using VigiBase and a systematic literature review. Expert Opin Drug Metab Toxicol 2022; 18 (11): 715–727. doi: 10.1080/17425255.2022.2143325.
16. Ronaldson KJ et al. Pathophysiology of clozapine myocarditis: current hypotheses. CNS Drugs 2015; 29 (7): 591–603. doi: 10.1007/s402 63-015-0260-3.
17. Rajagopal S et al. Myocarditis with clozapine: pathophysiology and epidemiology. Curr Cardiol Rep 2024; 26 : 109–119. doi: 10.1007/s11886-024-01913-7.
18. Qubad M, Dupont G, Hahn M et al. When, why and how to re-challenge clozapine in schizophrenia following myocarditis. CNS Drugs 2024; 38 (9): 671–696. doi: 10.1007/s40263-024-01069-5.
19. Nielsen J et al. Monitoring guidelines for clozapine myocarditis. CNS Drugs 2016; 30 (7): 589–598. doi: 10.1007/s40263-016-0346-1.
20. Čéšková E. Akutní stavy spojené s psychofarmakoterapií. Čes a slov Psychiat 2024; 120 (6): 277–282.
21. Kerneis M, Cohen F, Combes A et al. Rationale and design of the ARAMIS trial: Anakinra versus placebo, a double-blind randomized controlled trial for the treatment of acute myocarditis. Arch Cardiovasc Dis 2023; 116 (10): 460–466. doi: 10.1016/j.acvd.2023.03.005.
22. Státní ústav pro kontrolu léčiv. Klozapin: upravená doporučení pro rutinní sledování krevního obrazu. Praha: SÚKL; 11. červenec 2025. [online]. Dostupné z: https: //www.sukl.cz
23. Mayerová M. Opětovné nasazení klozapinu. Psychiatrie pro praxi 2023; 24 (2): 85–89.
24. Patel RK, Moore AM, Piper S. Clozapine-induced myocarditis: a systematic review of case reports. Acta Psychiatr Scand 2021; 143 (4): 355–369. doi: 10.1111/acps.13269.
25. Shankar R, Chakraborty I, Sinha S et al. Successful clozapine rechallenge following myocarditis: case report and review of the literature. Asian J Psychiatr 2020; 54 : 102430. doi: 10.1016/j.ajp.2020.102430.
26. Masopust J, Kopeček M, Bláha V. Sledování duševního zdraví u pacientů se závažnými neorganickými duševními poruchami. Doporučené postupy psychiatrické péče Psychiatrické společnosti ČLS JEP. [online]. Dostupné z: https: //postupy-pece.psychiatrie.cz
27. Masopust J. Augmentace klozapinu aripiprazolem u nemocných se schizofrenií. Psychiatrie 2018; 22 (3): 147–150.
Labels
Addictology Paediatric psychiatry PsychiatryArticle was published in
Czech and Slovak Psychiatry
2025 Issue 5
Most read in this issue
- Clozapine-induced myocarditis
- Dual disorder – how (in) consistent terminology affects research, diagnosis, and treatment
- Vortioxetine’s 10 years in Czech psychiatry – history of development and new findings
- Tokophobia: a hidden fear with serious consequences – a challenge for psychiatry and obstetrics